Skip to main content
Caplight Logo









MAAsiRNA

MAAsiRNA

Private
PalaiseauHealthcare & Life Scienceshttps://www.maasirna.com/

Last Round

Accelerator

Nov 24, 2023

Total Funding Raised

$750,000

Company Overview

MAAsiRNA is a biotechnology company that develops siRNA-based targeted therapies for nervous system pathologies, including Charcot-Marie-Tooth disease type 1A.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

siRNAsmall interfering RNAgene silencingbiotech startupdrug discoveryprecision medicinegene therapyCharcot-Marie-Tooth diseaseCMT1Ademyelinating diseasesperipheral neuropathytherapeutic platformRNA therapeuticsbiopharmadrug development

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

MAAsiRNA Comparables

Compare MAAsiRNA with similar companies based on industry and business-model similarity.

MAAsiRNA comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Armatus Bio
86%
Shark Tooth Bio
84%
Nervosave Therapeutics
83%

MAAsiRNA Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
AcceleratorNov 24, 2023

MAAsiRNA Investors

Notable investors and investment history

MAAsiRNA investors
InvestorRounds
SATT Paris-SaclayAccelerator

Market signals

Structured signals derived from secondary market and firmographic data.

  • Nov 24, 2023

    $750K raised, led by SATT Paris-Saclay.

MAAsiRNA Filings

Explore SEC and related filing metadata, where available.

MAAsiRNA filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about MAAsiRNA's valuation, stock price, and market status.

Is MAAsiRNA a public or private company?

MAAsiRNA is a private company.

What is the current stock price of MAAsiRNA?

MAAsiRNA is a private company with no public stock price. Caplight tracks MAAsiRNA's secondary market activity and provides MarketPrice™ estimates to Caplight users.

How much is MAAsiRNA worth (valuation)?

Valuation information for MAAsiRNA is not publicly available.

Can I buy MAAsiRNA stock?

MAAsiRNA shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was MAAsiRNA's last funding round?

MAAsiRNA's most recent funding round was Accelerator on November 24, 2023.

Who are the main investors in MAAsiRNA?

Key investors in MAAsiRNA include SATT Paris-Saclay.

Will MAAsiRNA IPO soon?

No public IPO plans have been announced for MAAsiRNA.

How can I track MAAsiRNA secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor MAAsiRNA's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersPalaiseau
Year Founded2024
Last FundingNov 24, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?